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Information leaflet given to participants 
PLEASE READ CAREFULLY BEFORE PROVIDING SPECIMENS 
Sputum examination for TB and the DETECTB research project  
We have recommended a sputum test for TB because you (or a member of your household) 
have told us that you have been: - 
 Coughing for the last 2 weeks or more 
 Or have other TB symptoms such as coughing up blood, sweating at night, pain in the 
chest, weight loss and poor appetite 
People with TB can have only mild symptoms but be infectious for many months or even 
years, putting their families and friends at risk of catching TB 
 
What is TB? 
 TB is an infection that is spread by coughing   
 Not everyone who catches TB becomes sick 
 TB is curable, but it is possible to die or become disabled from TB  
 
How can I tell if I have TB? 
 You can only tell if you have TB by having tests 
 The first step is to look in the sputum for TB bugs – the test we will be doing 
This test is routinely recommended for everyone with a cough lasting three weeks or more 
to help reduce the spread of TB 
 
What does it mean if the sputum test is positive? 
If TB bugs can be seen in sputum using strong light then it means 
 That you have TB affecting the lungs 
 That you are infectious to other people 
 That TB is the likely cause of any TB symptoms that you have 
 That you need to be treated for TB 
TB treatment is provided for free by the government 
 
What will happen to me if the sputum test is positive? 
 We will contact you in the next 4 days to tell you of a positive result 
 We will take more sputum to confirm the result, and will then refer you for free TB 
treatment by Harare City Health 
 You will be offered an HIV test as well as TB treatment – but you do not have to have 
this if you do not want to and no-one will test you for HIV without your knowledge 
and written permission 
 
What does it mean if the sputum test is negative? 
 We will not tell you if the sputum test is negative  
If we do not contact you within the next 4 days then your test was negative 
 A negative sputum test does NOT mean that you do not have TB 
o You could still have TB deep in the lungs or elsewhere in the body 
 This type of TB is much less infectious to other people  
 This type of TB still needs to be treated, but is more difficult to diagnose 
Take the ticket to Beatrice Road Hospital and we will do more TB tests 
 
Why is the DETECTB research study doing sputum tests for free?  
We are responding to the increasing problem with TB   
 We want to see if we can improve the control of TB by providing extra services to pick 
up infectious people more quickly, so reducing the spread of infection 
 We want to see which is more effective - mobile clinics or household enquiries?  
 
Who is doing the DETECTB study? 
BRTI, City Health Harare, London School of Hygiene & Tropical Medicine, UK, funded 
by the Wellcome Trust, a medical charity. We are working with Ministry of Health & 
Child Welfare. 
 
Could having the sputum test harm me in any way? 
The test itself will not harm you. The only risks would be from 
 Mistaken (false) positive results.  To reduce this risk as low as possible we will 
confirm all positive tests before referring for TB treatment 
 Bad reactions from other people if the sputum test shows that you have TB.  This is a 
risk, but we will keep your results confidential, so that it is up to you who you tell     
 
What if I do not want to participate in this study? 
 You do not have to participate in any way if you do not want to 
 Simply return the sputum pots empty or tell the study team that you do not want to 
have your sputum test carried out and we will not trouble you again   
For more information contact the DETECTB team on (Tel) 
 
IF YOU WANT YOUR SPUTUM TO BE CHECKED FOR TB 
 Use the two pots provided 
 Rinse your mouth with water and then go outdoors 
 Take a deep breath and cough deeply 
 If you bring up sputum (like jelly) into your mouth then spit it out into the pot 
o To do this test we need sputum and NOT just watery spit from the mouth 
 If you don’t bring up sputum keep on taking deep breaths and coughing until you do, 
or keep the pot with you and wait until you cough and bring up sputum naturally 
 Make sure that the lid is fastened tightly when you have finished 
 Take one specimen first thing in the morning before eating or drinking 
 Leave the pots at home to be collected, or take them to the mobile clinic if there is one 
in your neighbourhood.  Be sure to leave your correct address    
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Procedures 
 
To monitor delivery of the intervention, one in 20 households in door-to-door clusters were chosen at random and revisited by a 
supervisor immediately after completion of each cluster-round to ensure that all households had been visited as planned.  
Unannounced supervisor spot visits (at least twice per month) were used to monitor the activity of the mobile van team.   Patients 
diagnosed with TB through both arms had check of residential address at the time of delivering results (with reassurance that there 
would be no penalty for being non-resident), and again through cross-check of the address given to municipal services for 
registration of treatment.  A community liaison system and advisory board was in place. 
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Smear-positive participants in both intervention groups were referred to the DETECTB clinic, situated within the main TB 
registration centre in Harare for chest radiography and collection of two further sputum specimens.  Patients were referred to 
adjacent Municipal services for treatment of TB and HIV management.  HIV testing and care were not part of the community-
level active case-finding intervention, but diagnostic HIV testing was offered to all participants attending for facility management.  
Patients testing HIV positive were started on cotrimoxazole and referred to an adjacent HIV care clinic.  Treated TB patients were 
asked to return for assessment one month into treatment and on treatment completion, with active follow-up of defaulters. 
Transportation fares were refunded at each clinic attendance.      
 
All patients diagnosed with TB during the study had confirmatory sputum microscopy and culture and chest radiography at the 
time of referral for TB treatment.  The primary outcome analysis was restricted to patients with positive smears on > 1 specimen 
collected though active case-finding, residing in an intervention cluster, and with TB disease confirmed on microscopy and culture 
of follow-up specimens.  
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All specimens from the two prevalence surveys were cultured for TB.  Slides for microscopy were prepared from all specimens, 
but only stained and read if a) the participant had reported symptoms of TB, or b) there was growth on culture.  All positive and 
10% of negative slides were re-read by a second reader.  Positive slides were confirmed with Ziehl-Neelsen staining.  Culture used 
Lowenstein-Jensen (LJ) slopes, with residual concentrate stored at -20oC for re-culture in case of contamination.  M.tuberculosis 
was identified through colony morphology, cording, and growth characteristics.  Patients with non-tuberculous mycobacterial 
isolates had repeat specimens taken for microscopy and culture to minimise misclassification errors.  
 
Findings of the pre-intervention survey have been described previously in more detail  (1).   
 
1.  Corbett EL, Bandason T, Cheung YB, Makamure B, Dauya E, Munyati SS, Churchyard GJ, Williams BG, Butterworth AE, 
Mungofa S, Hayes RJ, Mason PR. Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and 
implications for control. Int J Tuberc.Lung Dis 2009;13(10):1231-7. 
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Participation rates for the two prevalence surveys (secondary outcome) 
 
 
   Before intervention                       At the start of Round 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a.  Included in analysis of change in prevalence of culture-positive TB for secondary outcome  
b. Based on enumeration of men and women in households selected.  
c.  403 (3.7%) individuals screened for TB in the end-intervention prevalence survey had participated in round 6 of the study 
intervention, 6 of whom had culture positive TB.  
  
1,199 adults not located in 
3 visits  
10,092 adults screened for TB with 
sputum culture a 
Mean 219 per cluster (range 115 - 375) 
81% (10 092/12 426) adult residents 
from households selected participated 
(65% [3970/6151] of male residents and 
98% [6121/6275] of female residents b). 
11,227 adults located 
10,236 adults interviewed 
991 declined interview  
144 declined TB screen 
2,446 adults not located in 
3 visits 
11,211 adults screened for TB with 
sputum culture a,c 
Mean 244 per cluster (range 130 - 422) 
77% (11 211/14 569) of adult residents 
from households selected participated 
(57% [4061/7185] of male residents and 
97% [7150/7384] of female residents b). 
 
 
12,123 adults located 
11,439 adults interviewed 
684 declined interview  
228 declined TB screen 
12,426 adult selected 14,569 adults selected 
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Characteristics of participants providing sputum specimens in the two prevalence surveys included in the analysis of 
secondary outcome 
 
Variable Pre-intervention 
N=10,092 a 
End intervention 
N=11,211 a 
 
Gender    
Male  3,970 (39.3%) 4,061 (36.2%)  
Age in years  
      Overall mean (SD) 
       <25 
      25-44 
      ≥45  
 
31.2 (13.0) 
4,132 (40.9%) 
4,472 (44.3%) 
1,488 (14.7%) 
 
31.9 (13.2) 
4,183 (37.3%) 
5,259 (46.9%) 
1,695 (15.1%) 
 
HIV testing and antiretroviral therapy    
Tested for HIV 9,062 (89.8%) b 9,851 (87.9%)  
HIV-positive (% of those tested)  1,916 (21.1%) 1,845 (18.7%)  
On antiretroviral therapy (% of HIV +ve) Data not collected 83 (4.7%)  
Smoking     
       Current  867 (8.6%) 893 (8.0%)  
       Former 196 (1.9%) 255 (2.3%)  
TB treatment    
Previous TB treatment  334 (3.3%) 370 (3.3%)  
Currently on TB treatment 74 (0.7%) 65 (0.6%)  
Number of household members with TB in past 
2 years 
       None 
       1 
       ≥2 years 
 
 
8,775 (86.9%) 
1,102 (10.9%) 
215 (2.1%) 
 
 
10,036 (89.5%) 
891 (8.8%) 
194 (1.7%) 
 
Education level 
       None or primary  
       1-2 years secondary  
       3-6 years secondary 
       Higher level 
 
1,644 (16.3%) 
1,040 (10.3%) 
6,956 (69.0%) 
446 (4.4%) 
 
1,543 (13.8%) 
1,051 (9.4%) 
7,868 (70.3%) 
730 (6.5%) 
 
    
a.  Answered symptom questionnaire and, irrespective of symptoms, provided sputum for culture.  Includes 31 and 29 participants 
in pre- and end- surveys who consented to provide sputum specimens, but were asymptomatic and unable to expectorate and so 
are assumed to be culture-negative. 
b. Two participants tested for HIV had indeterminate infection status. 
